Lyell Immunopharma (LYEL)
NASDAQ:LYEL
US Market
Holding LYEL?
Track your performance easily

Lyell Immunopharma (LYEL) Financial Statements

89 Followers

Lyell Immunopharma Financial Overview

Lyell Immunopharma's market cap is currently ―. The company's EPS TTM is $-0.829; its P/E ratio is -1.49; Lyell Immunopharma is scheduled to report earnings on February 26, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 13.00K$ 3.00K$ 13.00K$ 25.00K$ 27.00K
Gross Profit$ 13.00K$ 3.00K$ 13.00K$ 25.00K$ 27.00K
EBIT$ -45.81M$ -60.67M$ -59.51M$ -50.85M$ -63.89M
EBITDA$ -36.54M$ -60.01M$ -54.45M$ -48.04M$ -60.90M
Net Income Common Stockholders$ -45.81M$ -60.67M$ -52.93M$ -50.85M$ -63.89M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 491.12M$ 526.30M$ 546.22M$ 575.43M$ 595.75M
Total Assets$ 654.14M$ 694.22M$ 750.03M$ 794.99M$ 835.35M
Total Debt$ 53.32M$ 55.16M$ 56.89M$ 58.58M$ 60.22M
Net Debt$ -437.80M$ -471.14M$ -489.33M$ -516.86M$ -535.53M
Total Liabilities$ 87.64M$ 91.06M$ 95.08M$ 97.42M$ 98.50M
Stockholders Equity$ 566.50M$ 603.16M$ 654.95M$ 697.57M$ 736.86M
Cash Flow-
Free Cash Flow$ -38.42M$ -42.05M$ -40.66M$ -37.88M$ -40.09M
Operating Cash Flow$ -38.09M$ -42.02M$ -40.63M$ -37.69M$ -39.16M
Investing Cash Flow$ 45.01M$ 21.99M$ -100.69M$ 99.67M$ 152.91M
Financing Cash Flow$ 862.00K$ 27.00K$ 759.00K$ -143.00K$ 1.20M
Currency in USD

Lyell Immunopharma Earnings and Revenue History

Lyell Immunopharma Debt to Assets

Lyell Immunopharma Cash Flow

Lyell Immunopharma Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis